Molecular Markers in Thyroid Fine-needle Aspiration Biopsy

Franco, Carmen; Martínez, Virginia; Allamand, J; Medina, Francisco J.; Glasinovic, Andrea; Osorio, M Jaime; Schachter, Dina

doi:10.1097/pai.0b013e31818935a9

Cited by 60 publications

(31 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported data demonstrated that the combined use of markers had a better sensitivity and specificity than using each of the markers separately. This may help distinguish indeterminate or suspicious samples with a low or high risk of malignancy, thereby enabling a more adequate surgical selection [52][53][54][55]. Fadda et al and Rossi et al also found that the preoperative application of these markers on LBC in suspicious samples can effectively distinguish lesions, which need immediate surgery from those which can be followedup [56,57].…”

Section: Discussionmentioning

confidence: 92%

Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules

Raouf

Hamid

2014

Pathology - Research and Practice

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules

Raouf

Hamid

2014

Pathology - Research and Practice

View full text Add to dashboard Cite

“…68 Formalin-fixed paraffin-embedded cell blocks were created from the FNAB specimens and stained for Gal-3 using an ABC-detection system. Cytoplasmic staining of more than 10% of thyroid cells was required for Gal-3 positivity, and FNAB and pathological specimens underwent independent pathologist review.…”

Section: Immunocytochemical Studies Evaluating Gal-3 Expression In Nementioning

confidence: 99%

Diagnostic Utility of Galectin-3 in Thyroid Cancer

Chiu

Strugnell

Griffith

et al. 2010

The American Journal of Pathology

135

View full text Add to dashboard Cite

Galectin-3 (Gal-3), which has received significant recent attention for its utility as a diagnostic marker for thyroid cancer, represents the most well-studied molecular candidate for thyroid cancer diagnosis. Gal-3 is a protein that binds to ␤-galactosidase residues on cell surface glycoproteins and has also been identified in the cytoplasmic and nuclear compartment. This marker has been implicated in regulation of normal cellular proliferation and apoptosis, as well as malignant transformation and the metastasis of cancer cells. We here present a mechanistic review of Gal-3 and its role in cancer development and progression. Gal-3 expression studies in thyroid tissue and cytologic tumor specimens and their methodological considerations are also discussed in this article. Despite great variance in their methodology, the majority of immunohistochemical studies found that Gal-3 was differentially expressed in thyroid carcinoma compared with benign and normal thyroid specimens, suggesting that Gal-3 is a good diagnostic marker for thyroid cancer. Recent studies have also demonstrated improved methodological reliability. On the other hand, Gal-3 genomic expression studies have shown inconsistent results for diagnostic utility and are not recommended. Overall, the development of Gal-3 as a diagnostic marker for thyroid cancer represents a promising avenue for future study, and its clinical application could significantly reduce the number of diagnostic thyroid operations performed for cases of indeterminant fine needle aspiration biopsy cytology, and thus positively impact the current management of thyroid nodular disease. (Am J

show abstract

“…One flaw of this study was the relatively small number of indeterminate thyroid lesions included. Several other studies have looked at the accuracy of HBME-1 staining alone and found that HBME-1 ICC had a sensitivity of 79-87% and specificity of 83-96% in differentiating benign from malignant indeterminate thyroid nodules [66][67][68].…”

Section: Hbme-1 Cxcr4 Ck19 and Other Markersmentioning

confidence: 98%

Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations

Keutgen

Filicori

Fahey

2013

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Indeterminate thyroid lesions are diagnosed in up to 30% of fine needle aspirations. These nodules harbor malignancy in more than 25% of cases, and hemithyroidectomy or total thyroidectomy has therefore been advocated in order to achieve definitive diagnosis. Recently, many molecular markers have been investigated in an attempt to increase diagnostic accuracy of indeterminate fine needle aspiration cytology and thereby avoid unnecessary complications and costs associated with thyroid surgery. Somatic mutation testing, mRNA gene expression platforms, protein immunocytochemistry and miRNA panels have improved the diagnostic accuracy of indeterminate thyroid nodules, and although no test is perfectly accurate, in the authors' opinion, these methods will most certainly become an important part of the diagnostic tools for clinicians and cytopathologists in the future.

show abstract

Molecular Markers in Thyroid Fine-needle Aspiration Biopsy

Abstract: With the combined use of HBME-1 and galectin-3 in indeterminate FNABs, a 10% increase in sensitivity is achieved. These markers show excellent sensitivity and specificity and may improve patient's selection for surgery.

Cited by 60 publications

References 25 publications

Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules

Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules

Diagnostic Utility of Galectin-3 in Thyroid Cancer

Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations

Contact Info

Product

Resources

About